

References

1. Guidelines and clinical protocols of care "Hypertension". MOH, Ukraine № 384 from 24.05.2012. Kyiv, 2012.p.107.
2. Radchenko A.D. *Arterialna hipertenzia – Arterial hypertension* 2012;2:134–47.
3. Radchenko A.D. *Arterialna hipertenzia – Arterial hypertension* 2012;3.
4. Syrenko Y.M. Hypertension (manual for physicians).M.:Morion,2002.201 p.
5. 2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013;31:1281–357.
6. Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S. Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both : The ONGoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. *Circulation* 2010;121:1439–1446.
7. Boutouyrie P, Achouba A, Trunet P, Laurent S; EXPLOR Trialist Group. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study. *Hypertens* 2010;55:1314–22.
8. Byrd JB, Zeng C, Tavel HM, Magid DJ, O'Connor PJ, Margolis KL, Selby JV, Ho PM. Combination therapy as initial treatment for newly diagnosed hypertension. *Am Heart J* 2011;162(2):340–6.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertens* 2003;42 (6):1206–52.
10. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and Eprosartan: Differential Effects on Central Blood Pressure and Aortic Pulse Wave Velocity Atenolol and Eprosartan: Differential Effects on Central Blood Pressure and Aortic Pulse Wave Velocity (CAVI). *Am J Hypertens* 2006;19:214–9.
11. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. *Blood Pressure* 2003;12,Suppl.2:29–34.
12. Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, Mugellini A. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. *Am J Hypertens* 2004;17:77–81.
13. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. *Eur J Clin Pharmacol* 2002;58:177–180.

14. Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlini L, Fortino I, Cesana G, Mancia G. Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice. *Hypertension* 2011;58:566–572.
15. Girerd X. et al. / Analysis of the use of antihypertensive drugs in five European countries in 2010 / ESH London 29th April.
16. Gómez-Marcos MA, Recio-Rodríguez JI, Rodríguez-Sánchez E, Castaño-Sánchez Y, de Cabo-Laso A, Sánchez-Salgado B, Rodríguez-Martín C, Castaño-Sánchez C, Gómez-Sánchez L, García-Ortiz L. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol. *BMC Public Health* 2010;10:143.
17. Guido Grass GI, Quarti-Trevano F, Mancia G. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. *J Renin-Angiotensin-Aldosterone System* 2008;9:66–74.
18. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor “beyond blood pressure lowering”: beyond blood pressure or beyond the brachial artery? *J Hypertens* 2005;23:551–6.
19. Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M, Furukawa T, Takenaka T, Saruta T. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. *Am J Kidney Dis* 2005;45:866–74.
20. Kakou A1, Bézie Y, Mercier N, Louis H, Labat C, Challande P, Lacolley P, Safar ME. Selective reduction of central pulse pressure under angio-tensin blockage in SHR: role of the fibronectin– $\alpha 5\beta 1$ integrin complex. *Am J Hypertens* 2009;22:711–7.
21. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. *Eur Heart J* 1993;14:160–7.
22. Kifor IL, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. *J Urol* 1997;157:1920–5.
23. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson C 3rd, Cheitlin M, Debusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference). *Am J Cardiol* 2005; 96: 313–21.
24. Labat C, Lacolley P, Lajemi M, de Gasparo M, Safar ME, Benetos A. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. *Hypertension* 2001;38:439–43.
25. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension* 2001;37:1236–41.

26. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA, Ferrario CM. Sexual dysfunction in hypertensive patients treated with losartan. *Am J Med Sci* 2001;321:336–41.
27. London G. Central blood pressure reduction: a key to organ protection. *Medicographia* 2005;27:144–7.
28. London GM, Asmar RG, O'Rourke MF, Safar ME, REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. *J Am Coll Cardiol* 2004;43:92–9.
29. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB. Comparison of the Effects of Antihypertensive Agents on Central Blood Pressure and Arterial Stiffness in Isolated Systolic Hypertension. *Hypertens* 2009;54:409–13.
30. Mahmud A., Feely J. Antihypertensive drugs and arterial stiffness. *Expert Rev Cardiovas Ther* 2003;1:65–78.
31. Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, McG Thom SA, Hughes AD; Anglo-Scandinavian Cardiac Outcome Trial Investigators. Differences in the Magnitude of Wave Reflection Account for Differential Effects of Amlodipine- Versus Atenolol-Based Regimens on Central Blood Pressure An Anglo-Scandinavian Cardiac Outcome Trial Substudy. *Hypertens* 2009;54:724–30.
32. Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients. *Hypertens* 2009;54:716–23.
33. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockcroft JR, Wilkinson IB; Anglo-Cardiff Collaborative Trial Investigators. Variability and Impact of Cardiovascular Risk Factors The Anglo-Cardiff Collaborative Trial II. *Hypertens* 2008;51:1476–82.
34. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. *Am J Hypertens* 2004;17:118–23.
35. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andréjak M; investigators of the STRATHE trial. Investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. *J Hypertens* 2004;22:2379–86.
36. Nakamura M, Sato K, Nagano M. Estimation of aortic systolic blood pressure in community-based screening: the relationship between clinical characteristics and peripheral to central blood pressure differences. *J Hum Hypertens* 2005;19:251–3.
37. Nichols W., O'Rourke M., McDonald's Blood Flow in Arteries: theoretical, experimental and clinical principles. V ed. London, United Kingdom: Hodder Arnold, 2005:166–267.
38. Protogerou A, Blacher J, Stergiou GS, Achimastos A, Safar ME. Blood Pressure Response Under Chronic Antihypertensive Drug Therapy: rax in Regression of Arterial The Role of Aortic Stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) Study. *J Am Coll Cardiol* 2009;53:445–51.

39. Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among malay hypertensive subjects with a known genetic profile. *Am J Hypertens* 2007;20:184–9.
40. Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High Central Pulse Pressure Is Independently Associated With Adverse Cardiovascular Outcome The Strong Heart Study. *J Am Coll Cardiol* 2009;54:1730–4.
41. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF) a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997;49:822–30.
42. Safar M., Protogerou A., Blacher J. Central Blood Pressure Under Angiotensin and Calcium Channel Blockade. *Hypertension* 2009;54:704–6.
43. Sharman JE, Stowasser M, Fassett RG, Marwick TH, Franklin SS. Central blood pressure measurement may improve risk stratification. *J Hum Hypertens* 2008;22:838–44.
44. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators CAFE Steering Committee and Writing Committee. Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. *Circulation* 2006;113:1213–25.
45. Toblli JE, Stella I, Inserra F, Ferder L, Zeller F, Mazza ON. Morphological changes in cavernous tissue in spontaneously hypertensive rats. *Am J Hypertens* 2000;13:686–92.
46. Toblli J, Stella I, Néstor Mazza O, Ferder L, Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats: beyond blood pressure control. *Am J Hypertens* 2004;17:516–22.
47. Tsang TS, Verzosa GC, Barnes ME, Al-Omari MA, Bailey KR, Cha SS, Seward JB, Pellikka PA, Gersh BJ, O’Rourke MF. Abstract 3163: central pulse pressure as a robust predictor of first atrial fibrillation: Study Of Atrial Fibrillation In High Risk Elderly (SAFFIHRE). *Circulation* 2008;118:1106.
48. Uehara G, Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index. *J Int Med Res* 2008;36:1094–102.
49. Ushiyama M, Morita T, Kuramochi T, Yagi S, Katayama S. Erectile dysfunction in hypertensive rats results from impairment of the relaxation evoked by neurogenic carbon monoxide and nitric oxide. *Hypertens Res* 2004;27:253–61.
50. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. *Am. J. Med* 2009;122:290–300.
51. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical values in the VALUE trial. *Lancet* 2004;363:2049–51.

52. White W. Blood pressure monitoring in Cardiovascular Medicine and Therapeutics. N. Jersey:Humana Press, 2001.308 p.
53. Wilkinson IB, Franklin SS, Hall IR, Tyrrell S, Cockcroft JR. Pressure Amplification Explains Why Pulse Pressure is unrelated to risk in young subjects. *Hypertens* 2001;38:1461–6.
54. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, van der Arend BJ, Shu YE, MacKay LS, Webb DJ, Cockcroft JR. Pulse-Wave Analysis Clinical Evaluation of a Noninvasive, Widely Applicable Method for Assessing Endothelial Function. *Arterioscler Thromb Vasc Biol* 2002;22:147–152.35, 82, 83.
55. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. *J Physiol* 2000;525:263–70.
56. Williams B1, Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators Impact of Heart Rate on Central Aortic Pressures and Hemodynamics Analysis From the CAFE (Conduit ArteryFunction Evaluation) Study: CAFE-Heart Rate. *J Am Coll Cardiol* 2009;54:705–13.
57. Zhou WJ, Wang RY, Li Y, Chen DR, Chen EZ, Zhu DL, Gao PJ. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. *PLoS One* 2013.10;8(9):e72102. doi: 10.1371/journal.pone.0072102.